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Abstract
BACKGROUND: Alloimmunization remains a significant complication of transfusion and has 
been associated with multiple factors, including inflammation, an important pathophysiologic 
mechanism in sickle cell disease (SCD). We explored whether alloimmunization is associated with 
disease severity in SCD.
STUDY DESIGN AND METHODS—Adult SCD patients were enrolled in a study of outcome 
modifying genes in SCD. Historical records of patients with SCD at two participating institutions 
were reviewed for data on antigen phenotype and alloimmunization. Differences in demographic, 
clinical and laboratory findings, end organ damage, and overall disease severity were then 
compared between alloimmunized and non-alloimmunized patients.
RESULTS—Of 319 patients, 87 (27%) were alloimmunized. Alloantibody specificities differed 
from those previously described, especially due to the significantly higher frequency of anti-S. 
Although alloimmunization was not associated with frequency of vaso-occlusive episodes, a 
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higher percentage of alloimmunized patients had chronic pain, as defined by daily use of short 
acting narcotics (p=0.006), long acting narcotics (p=0.013), or both (p=0.03). Additionally, 
alloimmunized patients had poorer survival (HR=1.92, p=0.01) and were more likely to have 
avascular necrosis (p=0.024), end-organ damage (p=0.049) and red cell autoantibodies (p<0.001), 
even after controlling for the effects of age, gender, and hemoglobin diagnosis. Alloimmunization 
was not associated with other SCD related complications, such as acute chest syndrome or stroke.
CONCLUSIONS—Alloimmunization in SCD may be associated with chronic pain, risk of end-
organ damage, and shorter survival. These novel findings suggest new directions for the 
investigation of immune response-mediated pathways common to alloimmunization and chronic 
pain.
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INTRODUCTION
Patients with sickle cell disease (SCD) continue to be transfused frequently, compared with 
the general population. In the 2006 Nationwide Inpatient Sample (NIS) data of the 
Healthcare Cost and Utilization Project, 25% of nearly 100,000 admissions of patients with 
SCD involved transfusion. Twenty-seven percent of patients admitted for vaso-occlusive 
crisis were transfused, and 37.6% of patients treated for acute chest syndrome were 
transfused. (S. Kamble, S.D. Reed, C. Grussemeyer, and M.J. Telen, unpublished data)
Alloimmunization is a common complication of transfusion therapy among patients with 
SCD. Among different study populations with SCD, reported rates of alloimmunization have 
ranged from 18-47% of patients.1 This represents a much higher rate than in other 
chronically transfused populations.2,3 Alloimmune reactions can be associated with 
significant morbidity in SCD, including delay in urgent treatment of stroke and acute chest 
syndrome due to difficulty finding compatible blood, delayed transfusion reactions, 
hyperhemolysis,4,5 and autoantibody formation6-8.
It is unknown why some patients become alloimmunized while the majority of patients do 
not. Frequency of transfusion, along with differences between prevalent antigen phenotypes 
among SCD patients as compared to US blood donors,1,3,9 are thought to contribute to the 
relatively high rate of alloimmunization among patients with SCD. This is further supported 
by data showing lower rates of alloimmunization in SCD populations with more similar 
distribution of blood group antigens between donors and recipients.10
Antigenicity of the disparate antigens is also an important but potentially complex 
determinant.11 Other factors described as affecting the development of alloimmunization in 
patients with SCD include gender, number of transfusions,3,9 and age at which transfusion 
therapy began.12,13 More recent data have suggested that the increased incidence of 
alloimmunization in patients with SCD may also be related to altered immune responses, 
themselves associated with on-going inflammation14 or the frequency of certain HLA 
antigens.15,16 In animal studies, the magnitude and frequency of inflammation appears to 
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affect alloimmunization.17 Further, a genetic polymorphism in Ro52 (SSA1;TRIM21) has 
been associated with age-dependent maturation of the immune system in response to red 
blood cell (RBC) antigen presentation.18 This could potentially be a marker to predict the 
ability of SCD patient to develop tolerance or produce antibodies beyond the neonatal 
period.
As our knowledge of the basic pathophysiology of SCD has expanded, so has our 
understanding that disease severity is dependent on a variety of complex interactions and 
multiple determinants, including genetic and environmental factors. We hypothesized that 
the development of alloantibodies in patients with SCD may therefore be associated with 
other SCD complications as well as overall disease severity.
MATERIALS and METHODS
This study was conducted as part of an Institutional Review Board-approved larger study of 
clinical outcome-modifying genes in adults with SCD. All participants gave written 
informed consent, and patient clinical and medical histories were obtained using 
standardized data collection forms that included questions about exposure to transfusion and 
measures of disease severity. In order to assess exposure to transfusion, patients were asked 
to estimate the number of units of blood received over their lifetime; documentation of 
lifetime transfusion episodes was generally unavailable. This history of transfusion was 
stratified into 5 categories: none, between 1-10 units, between 11-20 units, between 21-50 
units, or >50 units. Patients were also asked if they were currently receiving chronic 
transfusion therapy or iron chelation treatment. Measures of disease severity included vaso-
occlusion-related endpoints, such as the number of acute painful episodes requiring 
hospitalization in the past 12 months, and significant chronic pain, as assessed by use of 
daily narcotics, as well as the presence of documented end-organ damage. The overall 
disease severity of each patient was then determined using a modified version of a 
previously validated chronic disease severity score measuring cumulative end-organ 
damage.19-22 A score for each patient was calculated based on the presence or absence of 
each of the following: 1) pulmonary dysfunction as defined by the presence of tricuspid 
regurgitant jet velocity ≥ 2.5 m/sec or O2 saturation <92%; 2) radiologically demonstrated 
avascular necrosis (AVN) of the hip or shoulder; 3) central nervous system (CNS) 
abnormality, as defined by a history of stroke, seizure, or transient ischemic attack (TIA); 4) 
kidney dysfunction, as defined by proteinuria ≥ 1+ on urinalysis or creatinine >1.0 mg/ml; 
and 5) history of leg ulcers. For each item, one point was assigned if present. The points 
were added to obtain a final score, which ranged from 0 points (mildest disease) to a 
possible maximum of 5 points (most severe disease).
Steady-state laboratory values (mean of up to three values) were also obtained for all 
patients. For patients on hydroxyurea treatment when enrolled, baseline hematologic data, 
defined as the mean of up to three steady-state samples collected prior to hydroxyurea 
treatment, were used for the analysis.
Within this larger study, historical blood bank records of 338 adult patients with SCD 
enrolled at two participating institutions (Duke University Medical Center and the 
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University of North Carolina at Chapel Hill) between March 2002 and January 2005 were 
reviewed to ascertain patient RBC phenotype and allo- and autoantibody data obtained 
through prior routine serologic testing. Identification of antigen phenotypes, alloantibodies 
and warm IgG autoantibodies had been performed using standard blood bank techniques. A 
patient was considered to be alloimmunized if their serum contained at least one antibody to 
an antigen absent from their own RBCs. Patients whose serum contained only cold-reacting 
autoantibodies, anti-I, anti-IH, anti-HLA, or so-called high titer low avidity (HTLA) 
antibodies, were not considered to be alloimmunized. Nineteen patients with incomplete 
blood bank records were excluded, leaving 319 subjects for analysis.
We then tested for differences between all immunized and non-alloimmunized patients with 
respect to demographic characteristics, history of transfusion exposures, clinical and 
laboratory findings, frequency of vaso-occlusive episodes, use of out-patient narcotics, the 
presence of end-organ damage, and overall disease severity, all of which had been 
ascertained using uniform case report forms as part of the larger study. Statistical analysis 
was performed using a standard statistical software package (SAS version 9.2, SAS Institute, 
Cary, NC). Chi-square tests were used for categorical variables, and the Fisher’s exact test 
was applied to data sets with cells containing less than five (5) observations. Logistic 
regression was then performed on nominally significant chi-square tests to obtain odds 
ratios. Analysis of Variance was used to compare the difference in means between all 
immunized and non-alloimmunized patients for continuous outcomes. Variables with 
significant departures from normality were log-transformed for analysis; these included 
HbF, creatinine, LDH, and ferritin. A p-value of <0.05 was considered significant. All tests 
were two-tailed.
RESULTS
Subject demographics and prevalence of alloimmunization
Of 319 adult patients with SCD and adequate information, 315 were self-identified as 
African American (99%) and 179 were female (56%). Patients ranged in age from 18 to 84 
years old (mean 35.1 years ± 12.2 SD [standard deviation]). The majority of the sample 
consisted of patients with HbSS (246/319, 77%), followed by HbSC (41/319, 13%), HbSβ+ 
thalassemia (17/319, 5%), and HbSβ0 thalassemia (15/319, 5%).
Eighty-seven patients had alloantibodies, with an overall alloimmunization prevalence of 
27%. Two of the three patients self-identified as Caucasian were alloimmunized; the one 
patient self-identified as Asian or Pacific Islander was not. Interestingly, within our adult 
cohort, alloimmunization was not related to age. The mean age of alloimmunized patients 
was 35.2 yrs, while that of non-alloimmunized patients was 35.1 yrs. Age at first 
alloimmunization was not available. Moreover, gender also did not have a statistically 
significant effect. Among women, 30.7% (55 of 179) were alloimmunized, while 22.9% of 
men (32 of 140) were alloimmunized (p>0.05). A comparison of the general demographic 
characteristics between alloimmunized and non-alloimmunized patients is shown in Table 1.
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Hemoglobin diagnosis and history of transfusion
As shown in Figure 1, hemoglobin (Hb) diagnosis was strongly associated with the presence 
of alloimmunization (p=0.004), with the highest percentage of alloimmunized patients being 
those with HbSβ0 thalassemia (46.7%) and the lowest percentage occurring in patients with 
HbSC (9.8%). Furthermore, Hb diagnosis was significantly associated with a history of 
transfusion (p=0.002). As expected, a history of any prior transfusion was also strongly 
associated with alloimmunization (p=0.017). Of the 285 patients who provided a transfusion 
history, 78/79 (98.73%) alloimmunized patients and 187/206 (90.78%) non-alloimmunized 
patients reported that they had been transfused, and only one alloimmunized subject (1/79, 
1.27%) had not been transfused. The one alloimmunized nontransfused subject had had two 
previous live births. However, after adjusting for the effects of Hb diagnosis, age, and 
gender, the association of alloimmunization with transfusion history no longer reached 
statistical significance. (OR=8.0; 95%CI 1.0 - 64; p=0.05), suggesting that Hb diagnosis was 
the driving factor for transfusion, and therefore for risk of alloimmunization. Perhaps 
surprisingly, alloimmunization did not appear to be directly related to the number of 
reported transfusions received, as the highest percentage of alloimmunized patients occurred 
among those who reported having received between 11 to 20 transfusions. In addition, the 
shape of distributions for transfusion history did not differ between alloimmunized and non-
alloimmunized patients (Cochran-Armitage trend test p=0.364). We also examined the 
potential association of alloimmunization with ferritin levels, possibly a more objective 
measure of transfusions received; while mean ferritin levels were higher among 
alloimmunized patients (p=0.05), this association was also driven by Hb diagnosis 
(p=0.001). Likewise, comparison of mean ferritin levels between the two groups was only 
minimally significant, with p=0.042 (Wilcoxon-Mann-Whitney test). Current treatment with 
chronic transfusion therapy or iron chelation therapy was also not associated with higher risk 
of alloimmunization. Five (6%) of 80 alloimmunized patients were currently receiving 
chronic transfusion therapy, compared to 7 (3%) of 212 non-alloimmunized patients 
(p=0.258). Similarly, 5 (6%) of 79 alloimmunized patients compared to 7 (3%) of 211 non-
alloimmunized patients were currently receiving iron chelation therapy (p=0.252).
Antibody specificities and frequency of autoantibodies
The most commonly occurring alloantibodies, in descending order of frequency, were anti-
E, -C, -S, -Fya or -Fy3, -Jkb, -K, and -M. Compared to the frequency of antigen specificities 
observed for alloantibodies in the Cooperative Study of SCD (see Table 2), our patients 
experienced significantly more frequent alloimmunization to the S, M, Jkb and V antigens 
(p<0.0001, p=0.013, p=0.025, and p=0.046, respectively) and less frequently made 
alloantibodies to the K antigen, although the difference in frequency of alloimmunization to 
K was not significant (p=0.106). No other differences approached statistical significance. 
Although our population was older than that examined by the CSSCD, we did not find a 
markedly greater proportion of alloimmunized patients who were multiply alloimmunized 
(Figure 2). Alloimmunized patients who made only one alloantibody comprised 44.97% of 
the alloimmunized CSSCD cohort and 37.93% of our study’s alloimmunized cohort 
(p=0.238). However, in the study by Rosse et al., 17.75% of 338 alloimmunized patients 
made four or more alloantibodies, while in our cohort, 28.73% of 87 alloimmunized patients 
made four or more alloantibodies (p=0.022).
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Alloimmunization was, nevertheless, strongly associated with the presence of a warm 
autoantibody, as 25% of alloimmunized patients had a warm autoantibody compared to <1% 
of non-alloimmunized patients (p<0.0001). Moreover, there was a very high prevalence of 
autoantibodies among patients alloimmunized against the E, V, S and Jkb antigens, and this 
reached statistical significance when compared to association with alloantibodies of other 
specificities. Among patients who made anti-E or anti-S, the prevalence of autoantibodies 
was 72.72% and 50%, respectively.
Relationship of alloimmunization to laboratory parameters
Mean steady-state laboratory values did not differ between alloimmunized and non-
alloimmunized patients, except in a very few instances (Table 3). Alloimmunized patients as 
a whole had slightly lower baseline hemoglobin levels (8.3 ± 1.6) compared to non-
alloimmunized patients (8.8 ± 2.0; p=0.04); while this difference was also observed within 
each hemoglobin diagnosis group, the differences within each diagnosis group were not 
statistically significant (data not shown). Ferritin levels, while higher in alloimmunized 
patients, demonstrated great variability of values within each group.
Relationship of alloimmunization to pain and measures of disease severity
Alloimmunization was not associated with a more frequent history of acute vaso-occlusive 
episodes, as defined by number of painful episodes requiring medical attention and/or 
hospitalization during the year prior to enrolment (Table 4). However, chronic pain, as 
defined by daily home opioid use, was associated with alloimmunization. This association 
was seen in patients who reported daily use of long-acting opioids (p=0.013), short-acting 
opioids (p=0.006), and both long-acting and short-acting opioids (p=0.03) but was strongest 
for short-acting opioids.
When the prevalence of SCD-related complications was measured (Table 5), we found that 
alloimmunization was significantly more common in patients with avascular necrosis 
(AVN) of the hip or shoulder, with 48% of alloimmunized patients having AVN compared 
with 33% of non-alloimmunized patients (p=0.024, Table 5). However, the prevalence of 
other disease complications did not vary between the two groups. In addition, the presence 
of AVN conferred an odds ratio of >2 for the daily use of opioids (p=0.005, p=0.002, and 
p=0.009 for association of AVN with long-acting, short-acting, and both).
We also compared overall disease severity between alloimmunized and non-alloimmunized 
patients using a multi-organ specific chronic disease severity score.22 The highest score for 
any individual patient, alloimmunized or non-alloimmunized, was four out of a possible five 
points. Alloimmunized patients were 1.5 times more likely to have organ damage compared 
to non-alloimmunized patients. (31% vs. 20%), and this difference was statistically 
significant (p=0.049). Furthermore, the prevalence of alloimmunization increased with 
increasing degrees of end-organ damage (p=0.028, Figure 3).
The results of multiple regression modelling of alloimmunization and significant bivariate 
associations, taking into account age, gender, and Hb diagnosis as covariates, are shown in 
Table 6. Alloimmunization remained a strong predictor of daily opioid use, even after 
adjusting for these covariates, with alloimmunized patients having 2 times the odds of daily 
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long-acting opioid use (p=0.016), daily short-acting opioid use (p=0.012) or both (p=0.048). 
However, female patients were only half as likely to be on long-acting opioids (OR=0.55, 
p=0.012) as males, regardless of alloimmunization status. Age was also a significant 
predictor of daily short-acting opioid use (OR 1.03, 95% CI=1.01-1.06, p=0.002), but its 
effect was modest compared to alloimmunization. A similar association was seen with 
alloimmunization and the presence of AVN. Alloimmunized patients had 2 times the odds of 
having AVN of the hip or shoulder, even after adjusting for age, gender, and Hb diagnosis 
(p=0.012). Age was a significant predictor of AVN (OR 1.05, 95% CI=1.03-1.07, 
p=<0.001), but its effect was modest compared to alloimmunization. While AVN 
independently affected the odds of daily narcotic use, its effect was small compared to the 
effect of alloimmunization, although its effect on the odds of using long-acting narcotics 
daily was somewhat greater.
Survival was strongly correlated with presence of alloimmunization, as shown in Figure 4. 
Despite similar frequency of painful episodes and hospitalizations, patients without 
alloimmunization had life expectancies about a decade longer than did alloimmunized 
patients.
We also performed subanalyses in which we compared non-alloimmunized subjects to only 
those who made alloantibodies to antigens other than C, E, and K (n = 66). In these analyses, 
lower hemoglobin was no longer statistically significantly associated with alloimmunization 
(p=0.192), but we again found statistically significant associations of alloimmunization with 
long-acting opioids (p=0.009), short-acting opioids (p=0.023) and both long and short-acting 
opioids (p=0.015), as well as AVN (p=0.047 when adjusted for hemoglobin diagnosis, 
gender and age, as in Table 6). Furthermore, this subset of alloimmunized patients still had 
poorer survival (HR=1.7889, p=0.0388) than nonalloimmunized patients.
DISCUSSION
Our study of a contemporary adult population with SCD shows both significant differences 
as well as similarities in the prevalence and pattern of alloimmunization compared to the 
landmark CSSCD study published over 20 years ago.9 First, while the CSSCD study 
demonstrated a prevalence of alloimmunization of 18.6% in a U.S. SCD population, we 
documented a prevalence of 27.3%. This difference is likely a result of studying only an 
adult cohort rather than one that included newborns and young children with limited 
exposure to transfusions. Similarly, in the more recent PROACTIVE study, which enrolled 
subjects with a mean age of 19.3 years (range, 2.0-68.0), 75.8% of whom had received at 
least one transfusion, the prevalence of alloimmunization was 14.4%.23 Interestingly, in that 
study, 50% of the adult patients found to be alloimmunized had received <10 units of blood, 
and there was no difference in alloimmunization rate between centers that prospectively 
matched for C, E and K and those that did not. Thus, both our study and the smaller one of 
Miller et al.23 suggest that alloimmunization is not clearly related to the number of prior 
transfusions. While our study showed a higher prevalence of alloimmunization, this was 
likely related to the higher mean age of our study subjects (>35 years), and the nearly 100% 
frequency of a history of transfusion.
Telen et al. Page 7
Transfusion. Author manuscript; available in PMC 2016 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
We also found interesting differences in the frequency of certain antibody specificities, 
including anti-S, anti-M, anti-Jkb, and anti-V, compared to the CSSCD report, while the 
frequency of antibodies to the C and E antigens were similar in the two studies. In both 
studies, however, anti-C, -E, -K, and –Fya were among the most frequent alloantibodies 
found. The increased frequency of anti-S in our study has also been found in some other 
studies, including one in Africa.24 Interestingly, the percentage of alloimmunized patients 
who had ≥4 alloantibodies was also significantly higher in our study compared to CSSCD 
(p=0.022). We cannot eliminate the possibility that the location of our study (two nearby 
institutions in North Carolina) or local transfusion practices contributed to both the 
frequency of alloimmunization as well as to the alloantibody specificities we found. In our 
state, the two university clinical centers that conducted this study have prospectively 
matched blood for C, E and K when transfusing SCD patients for > 30 years, while the local 
community hospitals in this quite rural state have not done so. Thus, our patients have often 
acquired anti-C and anti-E after transfusion at local community hospitals. Consequently, the 
prevalence of anti-C and anti-E are nearly identical to those reported in the CSSCD study, a 
study performed before most centers had adopted routine matching for C, E and K.
Recent studies have also shown that polymorphisms within the RH locus, but not routinely 
detected by D, C/c, E/e phenotyping, may be linked to alloimmunization to Rh antigens. 
Chou et al.25 reported 15 years’ experience transfusing 182 patients with SCD with donor 
units antigen-matched for RhD, C and E, and K, and selected primarily from African-
American donors. Despite these strategies, 80 patients (44%) became alloimmunized, and 94 
of 146 antibodies had Rh specificity. Thirty-five Rh alloantibodies occurred in antigen-
negative patients receiving corresponding D-, C- or E- RBCs who should not have made the 
antibody in the absence of exposure to antigen-positive RBCs. Fifty-six Rh antibodies 
occurred in patients whose RBCs were positive for the antigen in serological tests and would 
therefore have not been expected to recognize the antigen as foreign. The authors concluded 
that variant RH alleles in both patients and donors could result in unexpected Rh 
alloantibodies. In a smaller study, O’Suoji and colleagues found that efforts to antigen match 
blood for C, E, and K nevertheless resulted in a significant alloimmunization rate to these 
antigens; they implicated both episodic transfusion in institutions that did not provide 
phenotypically matched blood as well as sensitization in the presence of rare RH variants.26
In addition, the association of alloimmunization with autoantibody formation was quite 
striking in this study. In the previous study by Castellino et al., only two of 14 
autoantibodies were not associated with alloimmunization.6 As reviewed by Garratty,7 the 
mechanisms whereby alloimmunization and autoantibody formation may be associated are 
potentially of great interest and may include “epitope spreading” as well as more generalized 
activation of the immune system during alloantibody formation. Indeed, this association of 
alloimmunization and autoantibody formation is not limited to the SCD or even 
hemoglobinopathy population.8
Unlike the CSSCD study, our study has both sought to identify clinical characteristics 
associated with alloimmunization as well as to explore whether alloimmunization itself is a 
risk factor for other complications in SCD. We found that alloimmunization was strongly 
associated with the presence of chronic pain, as assessed by daily opioid use, a relatively 
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common finding in adult patients. In addition, alloimmunization was associated with AVN 
among adults with SCD. These findings have not been previously reported. However, such 
associations do not provide evidence of causation or even directionality of possible 
relationships.
Pain is a hallmark of sickle cell disease. Pain occurs frequently in the context of acute vaso-
occlusive episodes, and acute painful episodes are the predominant symptom associated with 
SCD. However, in adults pain is also often more chronic in nature and may have a 
neuropathic and/or inflammatory component.27 Thus, chronic pain syndromes in SCD are 
considered to be different in nature from acute vaso-occlusive episodes and have been 
associated with several disease complications, such as leg ulcers, bone and joint disease, or 
nerve disturbances.27 Among chronic pain syndromes, AVN is associated with deep somatic 
pain, often complicated by incident pain, that is, pain related to movement.28 Treatment of 
persistent moderate to severe pain generally relies on opioids.27
The mechanism of chronic pain in sickle cell disease is poorly understood, and current 
avenues of investigation include the PISCES study29,30 of the nature of pain in SCD as well 
as investigation of genetic polymorphisms that may explain predisposition to pain.31,32 
Studies suggest that most patients treat pain at home and that only when severity and acuity 
of pain increases sufficiently do they seek medical attention. Based on PISCES data, more 
patients than previously thought have daily pain that they treat at home.29,30 Thus, at this 
time, we can only speculate as to why chronic pain and alloimmunization to red cell blood 
group antigens may be associated events. It is possible that immune system activation might 
contribute both to the risk of alloimmunization as well as to development of chronic pain.
As in other studies, factors associated with alloimmunization included a history of 
transfusion, although this relationship was not directly related to the number of transfusions 
reported by patients. This lack of a relationship, however, may have resulted from the 
retrospective nature of the transfusion data (patient report). We did find a weak relationship 
between alloimmunization and ferritin level, which is assumed to result from transfusional 
iron burden, and the differences in mean ferritin between the two groups was quite large 
(1526.4 ± 2153.3 vs 914.3 ± 1612.2 ng/mL). This result suggests that subjects’ recall of the 
number of previous transfusions was not accurate and that ferritin, which was markedly 
higher in alloimmunized patients compared to non-alloimmunized patients, may be a better 
reflection of actual number of transfusions received. However, ferritin is also an acute phase 
reactant and thus might also reflect a more pro-inflammatory status among patients who 
have been alloimmunized. Age was not associated with alloimmunization in this study. 
However, all of the patients in this study were adults, and age of first transfusion was not 
known. Therefore, the potential effect of tolerance induction could not be assessed. Gender, 
also identified as a factor related to risk of alloimmunization, was not seen as significant in 
this study. Again, this could be secondary to the age distribution of the subjects in our study 
as compared to the CSSCD, since older age (and thus higher prevalence of a positive 
transfusion history) would be anticipated to make less significant the potentially 
alloimmunizing effect of pregnancy.
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Finally, the association of alloimmunization with shortened survival is particularly 
interesting, and this possible association has not been previously studied. Given that the 
prevalence of end-organ damage was only slightly increased in the alloimmunized cohort, 
and that the frequency of vaso-occlusive episodes requiring medical attention was not 
significantly increased, the mechanism of this difference in survival is particularly 
intriguing. We hypothesize that the pathways predisposing to chronic pain requiring daily 
opioids also lead to decreased survival, although what these pathways might be remains an 
open question at this time. Several lines of evidence implicate inflammatory pathways in 
chronic pain of SCD.25,26 Whether these mechanisms involve major genetic effects or result 
from stochastic disease-related events, the causes of the association of alloimmunization 
with decreased survival certainly merits further investigation.
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Figure 1. Percent alloimmunized patients with specific hemoglobin diagnoses
Patients with HbSS and HbS-β0 thalassemia were alloimmunized significantly more often 
than were patients with HbSC or HbS β+ thalassemia.
Telen et al. Page 12
Transfusion. Author manuscript; available in PMC 2016 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 2. Prevalence of having multiple alloantibodies among alloimmunized patients
Among patients who were alloimmunized, slightly less than 38% had only one alloantibody 
identified, while close to one-third had two or three alloantibodies, and nearly a third had 
four or more alloantibodies.
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Figure 3. Relationship of overall disease severity and alloimmunization, based on a multi-organ 
chronic disease severity score
Scores were calculated based on the presence or absence of 1) pulmonary dysfunction 2) 
kidney dysfunction 3) CNS abnormality, 4) AVN of hips or shoulders, and 5) leg ulcers, for 
a total possible score of 5. The highest observed score for an individual patient, 
alloimmunized or non-alloimmunized, was 4 out of the possible 5. Alloimmunization was 
increasingly prevalent with increased disease severity (p=0.028). In addition, only 20% of 
alloimmunized patients had no organ damage, compared to 31% of non-alloimmunized 
patients and this difference was statistically significant (p=0.049, data not shown)).
Telen et al. Page 14
Transfusion. Author manuscript; available in PMC 2016 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 4. Survival of alloimmunized and nonalloimmunized patients
Kaplan-Meier estimation of survival in patients with and without alloimmunization showed 
a median life expectancy of 65 years in nonalloimmunized patients but only 54 in 
alloimmunized patients.
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Table 1
Demographics of Alloimmunized vs. Non-alloimmunized Patients With Sickle Cell Disease (n=319)
Alloimmunized
N=87
(%)
Non-alloimmunized
N=232
(%)
P
value
Mean Age (years) 35.2 ± 10.1 35.1 ± 12.9 0.932
Gender
 Male
 Female
32 (23)
55 (31)
108 (77)
124 (69)
0.117
History of Transfusion (n=285)*
 None
 1-10
 11-20
 21-50
 >50
1 (1)
32 (41)
21 (27)
9 (11)
16 (20)
19 (9)
98 (48)
32 (16)
29 (14)
28 (14)
0.017
Warm Autoantibody 22 (25) 2 (<1) <0.001
*
Thirty-four (34) patients did not respond to this question.
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Table 2
Specificity of Alloantibodies Among Alloimmunized Patients, Compared to the Cooperative Study of SCD 
(CSSCD)9
Specificity % of
338
alloimm
CSSCD
Pts
% of 87
alloimm
Duke-
UNC
Pts
P value Specificity % of
338
alloimm
CSSCD
Pts
% of 87
alloimm
Duke-
UNC
Pts
P value
D 13.0 11.49 0.704 M 7.7 17.24 0.013*
C 30.2 35.63 0.364 N 1.5 1.15 1.000
c 3.0 2.30 1.000 S 9.2 29.89 <0.0001*
E 42.3 45.98 0.538 s 1.5 2.30 0.636
e 4.4 2.30 0.543 Jka 1.8 3.45 0.398
V 2.4 6.90 0.046* Jkb 10.7 19.54 0.025*
K 28.1 19.54 0.106 Fya or Fy3 18.6 24.14 0.251
*
Statistically significant difference between the two studies
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Table 3
Mean Laboratory Values in Alloimmunized vs. Non-alloimmunized Patients
N* Alloimmunized Non-
alloimmunized
P
value
Values ± S.D.
Hematologic
 Hemoglobin (g/dL) 230 8.3 ± 1.6 8.8 ± 2.0 0.040
 Hemoglobin F (%)
† 172 6.8 ± 5.2 6.3 ± 5.2 0.206
 Platelet count (× 109/L)
‡ 218 431.2 ± 172.1 426.3 ± 156.2 0.840
 WBC count (× 109/L) 220 11.5 ± 4.1 11.6 ± 3.6 0.886
 Abs. Reticulocyte Count
 (× 109/L)
201 301.0 ± 163.1 280.8 ± 135.8 0.375
Renal
 Creatinine (mg/dL)
ǁ 280 0.8 ± 0.4 0.9 ± 0.5 0.620
 Glomerular Filtration Rate
 (mL/min/1.73 m2)
270 100.4 ± 19.9 102.7 ± 20.4 0.402
Other
 Lactate Dehydrogenase
 (U/L) 
ǁ
277 1106.9 ± 691.6 1052.4 ± 687.7 0.333
 Ferritin (ng/mL) § 143 1526.4 ± 2153.3 914.3 ± 1612.2 0.042
*
Number of subjects for whom data were available.
†
Statistical analysis based on log-transformed value. Excludes one patient with hemoglobin F percentage greater than 30%.
‡
Excludes one patient with platelet counts greater than 1,000,000 X 109/L.
§
Statistical analysis based on log-transformed value.
ǁ
statistical analysis based on log-transformed value. Excludes six patients (three alloimmunized and three non-alloimmunized) with creatinine 
values greater than 4.7 mg/dL.
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Table 4
Comparison of Pain-Related Outcomes in Alloimmunized vs. Non-alloimmunized SCD Patients
N* % of
Alloimmunized
Patients
% of Non-
alloimmunized
Patients
P
value
Vaso-occlusive Endpoints
Painful episodes requiring
medical attention in past 12
months
Painful episodes requiring
hospitalization in past 12
months
294
291
77
61
71
57
0.339
0.539
Hydroxyurea use 282 50 48 0.708
Daily home opioid use
 Long-acting opioids
 Short-acting opioids
 Both long and short-acting
 opioids
295
276
275
39
47
28
24
29
16
0.013
0.006
0.030
*
Number of subjects for whom data were available.
Transfusion. Author manuscript; available in PMC 2016 June 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Telen et al. Page 20
Table 5
Prevalence of SCD-Related Outcomes in Alloimmunized vs. Non-alloimmunized Patients
N* % of
Alloimmunized
Patients
% of Non-
alloimmunized
Patients
P
value
Central Nervous System Endpoints
Stroke
Any cerebral vascular event
†
289
286
20
32
13
25
0.162
0.267
Pulmonary Endpoints
Acute chest syndrome
Tricuspid regurgitant jet velocity
≥ 2.5 m/s
Oxygen saturation < 92%
295
187
272
83
40
9
76
35
5
0.221
0.560
0.260
Other SCD-related Endpoints
AVN of hip or shoulder
Proteinuria ≥ 1 +
Leg ulcers
289
283
292
48
23
26
33
25
23
0.024
0.697
0.687
*
Number of subjects for whom data were available.
†
Includes stroke, transient ischemic attacks, and seizures.
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Table 6
Effect of Alloimmunization on Risk of Clinical Outcomes*
Variable OR 95% CI P value
Daily Narcotic Use
 Long Acting
 Short Acting
 Both Long & Short Acting
2.01
2.05
1.91
1.14, 3.55
1.17, 3.61
1.01, 3.62
0.016
0.012
0.048
AVN 2.08 1.18, 3.66 0.012
Chronic Organ Damage (any
vs. none)
1.53 0.809, 2.91 0.190
*
Results for alloimmunization (yes vs. no) adjusted for hemoglobin diagnosis (all types), gender (female vs. male) and age as a continuous 
variable.
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